Next generation sequencing (NGS) is a scientific tool that identifies genetic sequence. When used in oncology, NGS can allow doctors to test the genes in a patient's cancer at the same time, helping to identify an optimal therapeutic option.
-
Next-generation sequencing (NGS) based liquid biopsy is emerging as standard of care in oncology for comprehensive genomic profiling (CGP) of solid tumors. In this presentation we will showc...
Tumor genomic profiling can be complicated, especially for diseases that commonly have multiple different genomic biomarkers of interest, such as non-small cell lung cancer (NSCLC) and color...
Across various stages of the clinical oncology workflow, from panel design to genomic testing and molecular tumor boards, the identification and validation of actionable genomic alterations...
SiO2 Materials Science is a company with deep roots in materials science and engineering and a track record of innovative packaging products for pharmaceutical drugs. The company also manufa...
To bring your cutting-edge cell and gene therapies to the patients that need them as quickly as possible, you need access to the most knowledgeable scientists, innovative technologies, metho...
Description: Join this two-part webinar to learn how capillary electrophoresis (CE) complements sequencing technologies, such as next generation sequencing, that are being used by cancer res...
Description: Join this two-part webinar to learn when capillary electrophoresis is an ideal choice relative to other various sequencing technologies – such as next generation sequencin...
Epigenetic modifications such as DNA methylation have long shown promise as potential biomarkers to diagnose and guide treatment of many human diseases, including multiple types of cancers....
Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsi...
September 13 at 10:00am CEST, 9:00am BST
Webinar airing too early or too late for you? This webinar will also be available: September 13 at 10:00am PDT, 1:00pm EDT https://www.labroots.com/ms/webinar/dpcr-liquidbiopsy-panel-2 and S...
September 13 at 9:30am IST, 12:00pm CST/SGT
Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsi...
Advancements in Next Generation Sequencing (NGS) are changing the genomics industry, favoring those with scale. Quest Diagnostics' clinical expertise, combined with our infrastructure, p...
Liquid biopsies represent a transformation in the management of cancer as they have the potential to detect, characterize, and monitor cancers earlier than can be achieved with conventional...
Recent advances in multi-omic approaches, including genomics, transcriptomics, and proteomics, enable a more comprehensive description of the tumor. This promises to accelerate the developme...
MAR 30, 2023 | 1:50 PM
C.E. CREDITS
Liquid biopsy tests are an integral part of the molecular diagnostic workup of cancer specimens. We have performed extensive validation studies of the GeneStrat NGS test (GSNGS), that uses a...
Liquid biopsy tests are an integral part of the molecular diagnostic workup of cancer specimens. We have performed extensive validation studies of the GeneStrat NGS test (GSNGS), that uses a...
MAR 30, 2023 | 1:20 PM
C.E. CREDITS
...
MAR 30, 2023 | 12:25 PM
C.E. CREDITS
...
Dr. Ritterhouse's laboratory has implemented rapid and ultra rapid protocol for NSCLC genomic profiling, based on NGS. This has led to significant shortening of turn around time (TAT) an...